Related Experiment Videos
Classics in Chemical Neuroscience: Aripiprazole
Austen B Casey1, Clinton E Canal1
1Department of Pharmaceutical Sciences, Center for Drug Discovery, Northeastern University , Boston, Massachusetts 02115, United States.
ACS Chemical Neuroscience
|April 4, 2017
Summary
Aripiprazole, an atypical antipsychotic, offers a novel approach to schizophrenia treatment by targeting dopamine D2 autoreceptors. While effective for positive, negative, and cognitive symptoms with fewer side effects, it
Area of Science:
- Neuroscience
- Pharmacology
- Psychiatry
Background:
- Aripiprazole represents a novel antipsychotic class with dopamine D2 autoreceptor agonist properties.
- Traditional antipsychotics (D2 antagonists) cause movement side effects; second-generation agents have metabolic concerns.
- Aripiprazole's unique polypharmacology targets dopamine and serotonin receptors.
Purpose of the Study:
- To review the synthesis, pharmacology, and mechanisms of aripiprazole.
- To discuss its efficacy in treating schizophrenia symptoms.
- To examine its adverse event profile, including recent findings on compulsive behaviors.
Main Methods:
- Literature review of aripiprazole's chemical synthesis and pharmacology.
- Analysis of clinical data on efficacy and side effects.
- Exploration of pharmacogenomic and metabolic pathways.
Main Results:
- Aripiprazole effectively reduces positive, negative, and cognitive symptoms of schizophrenia.
- It demonstrates a lower risk of movement and weight gain side effects compared to older antipsychotics.
- A small subset of patients experienced compulsive behaviors as an adverse event.
Conclusions:
- Aripiprazole's unique pharmacology offers a balanced efficacy and tolerability profile for schizophrenia.
- Understanding its mechanisms is crucial for optimizing treatment.
- Further research is needed on rare adverse events like compulsive behaviors.